TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01948167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy- Adolescent Skills Training
Description: A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping with Stress
Description: A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
Study: NCT00526188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetic Acid Disodium (Primovist, BAY86-4873)
Description: Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
Study: NCT03716466

Intervention type: OTHER
Intervention: Endotracheal intubation
Description: Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure

Intervention type: OTHER
Intervention: No airway intervention
Description: Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
Study: NCT00771875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihistamine
Description: Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
Study: NCT01959360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified minimal invasive
Description: Total hip replacement; modified minimal invasive approach
Study: NCT02189265

Intervention type: OTHER
Intervention: Smoke-free legislation
Description: The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
Study: NCT02693964

Intervention type: OTHER
Intervention: Bone density and carotid ultrasound
Description: All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.

Intervention type: OTHER
Intervention: Bone density and carotid ultrasound
Description: All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
Study: NCT02082561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Treatment (F-SET)
Description: F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
Study: NCT02463942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Symptomatic therapy
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study: NCT02528695

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: euglycemic clamp
Description: euglycemic clamp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hypoglycemic clamp
Description: hypoglycemic clamp

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypoglycemic clamp
Description: hypoglycemic clamp
Study: NCT03792009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paracervical block
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Paracervical block
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% bupivacaine
Description: The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study: NCT01479972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: Tuberculosis vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: commercially available live vaccine BCG
Study: NCT03118843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Study: NCT00124618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00052377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03572335

Intervention type: DIAGNOSTIC_TEST
Intervention: PFT's (pulmonary function testing)
Description: The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.

Intervention type: DIAGNOSTIC_TEST
Intervention: PFT's (pulmonary function testing)
Description: The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
Study: NCT04050254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
Study: NCT01083264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gestodene/EE Patch (BAY86-5016)
Description: Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
Study: NCT00611364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy and education meetings
Description: Physical therapy was realized three two times per week and education meeting every fifteen days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education meetings
Description: This group only participed of education meeting (every fifteen days)
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM
Study: NCT03707717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT and orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally
Study: NCT00771875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
Study: NCT02989363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device O-Arm in DBS
Description: Deep brain stimulation surgeries with device O-Arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device O-Arm in RAQUIS
Description: Complex back surgeries with the device O-Arm
Study: NCT04402489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117 Low Dose
Description: MT-7117 Low Dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117 High Dose
Description: MT-7117 High Dose
Study: NCT01491958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: Given orally
Study: NCT02665715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate meals
Description: Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate meals
Description: Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard carbohydrate meals
Description: Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard carbohydrate meals
Description: Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
Study: NCT00599079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
Study: NCT05256147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Patient will receive ibuprofen 400 mg before the phototherapy session.
Study: NCT00573443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
Description: Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
Description: Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
Study: NCT04599998

Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire
Description: Participants will perform spirometry, lung diffusion capacity of carbon monoxide, 6-minute walk test (6MWT), Short form-36 (SF-36) questionnaire and cardiopulmonary exercise testing (CPET) after 6-12 months (Visit 1) of COVID-19. Clinical, laboratory and chest image data during the COVID-19 hospitalization will be obtained from medical records.
Study: NCT04266340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: 2.5µg/kg intranasal dexmedetomidine group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 0.5mg/kg oral midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 0.05mg/kg intravenous injection midazolam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: no premedication
Study: NCT00274651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Study: NCT02082808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV
Description: DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV
Description: DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet